Kinetics of morphine in patients with renal failure
- PMID: 3609116
- DOI: 10.1007/BF00543973
Kinetics of morphine in patients with renal failure
Abstract
The kinetics of morphine and its glucuronidated metabolites were investigated in seven patients with advanced renal failure. The terminal elimination half life of morphine varied between 1.5 and 4.0 h (mean 2.4 h), the volume of distribution between 2.5 and 6.3 l X kg-1 (mean 4.4 l X kg-1) and the total plasma clearance between 13.3 and 31.3 l X min-1 X kg-1 (mean 21.1 l X kg-1). There were no statistically significant differences between the pharmacokinetic data in the uraemic patients and in a control group of cancer patients with normal kidney function. The concentrations of the glucuronidated metabolites rapidly rose to levels above those of morphine. The elimination half-life of M3G varied between 14.5 and 118.8 h (mean 49.6 h) in the renal failure patients, which is distinctly different from the 2.4 to 6.7 h (mean 4.0 h) found in patients with normal kidney function. There was a significant correlation between the half-life of M3G and renal function estimated as serum urea. Thus, the metabolism of morphine in patients with kidney disease is not significantly impaired. The clinical importance of the high concentrations of glucuronides in uraemic patients is not known.
Similar articles
-
Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.Clin Pharmacokinet. 1993 Apr;24(4):344-54. doi: 10.2165/00003088-199324040-00007. Clin Pharmacokinet. 1993. PMID: 8491060
-
Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites.Br J Anaesth. 1989 Jan;62(1):28-32. doi: 10.1093/bja/62.1.28. Br J Anaesth. 1989. PMID: 2644963
-
Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.Eur J Clin Pharmacol. 1989;36(2):165-74. doi: 10.1007/BF00609190. Eur J Clin Pharmacol. 1989. PMID: 2721541
-
High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001. Clin Pharmacokinet. 1986. PMID: 3514045 Review.
-
Renal failure and the action of drugs.Prog Biochem Pharmacol. 1974;9:206-20. Prog Biochem Pharmacol. 1974. PMID: 4612557 Review. No abstract available.
Cited by
-
[The role of morphine-6-glucuronide during longterm administration of morphine.].Schmerz. 1992 Mar;6(1):8-12. doi: 10.1007/BF02529688. Schmerz. 1992. PMID: 18415586 German.
-
Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration.Eur J Clin Pharmacol. 1990;38(2):121-4. doi: 10.1007/BF00265969. Eur J Clin Pharmacol. 1990. PMID: 2338107
-
Respiratory depression following morphine and morphine-6-glucuronide in normal subjects.Br J Clin Pharmacol. 1995 Aug;40(2):145-52. Br J Clin Pharmacol. 1995. PMID: 8562297 Free PMC article. Clinical Trial.
-
Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease.Eur J Clin Pharmacol. 2010 Mar;66(3):269-73. doi: 10.1007/s00228-009-0759-8. Epub 2009 Nov 26. Eur J Clin Pharmacol. 2010. PMID: 19940985
-
Pharmacokinetics and dosage adjustment in patients with renal dysfunction.Eur J Clin Pharmacol. 2009 Aug;65(8):757-73. doi: 10.1007/s00228-009-0678-8. Epub 2009 Jun 20. Eur J Clin Pharmacol. 2009. PMID: 19543887 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous